Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki, E Michael; Keaveny, Tony M; Kopperdahl, David L; Genant, Harry K; Engelke, Klaus; Fuerst, Thomas; Kivitz, Alan; Davies, Richard Y; Fitzpatrick, Lorraine A.
J Clin Endocrinol Metab
; 94(1): 171-80, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18840641
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Adherence to bisphosphonate therapy in postmenopausal osteoporotic women.
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.